Literature DB >> 6181386

Specific binding of an immunoreactive and biologically active 125I-labeled substance P derivative to mouse mesencephalic cells in primary culture.

J C Beaujouan, Y Torrens, A Herbet, M C Daguet, J Glowinski, A Prochiantz.   

Abstract

Binding characteristics of 125I-labeled Bolton-Hunter substance P ([125I]BHSP), a radioactive analogue of substance P, were studied with mesencephalic primary cultures prepared from embryonic mouse brain. Nonspecific binding represented no more than 20% of the total binding observed on the cells. In contrast, significant specific binding--saturable, reversible, and temperature-dependent--was demonstrated. Scatchard analysis of concentration-dependent binding saturation indicates a single population of noninteracting sites with a high affinity (Kd = 169 pM). Substance P and different substance P analogues were tested for their competitive potencies with regard to [125I]BHSP binding. BHSP itself, substance P, (Tyr8)-substance P, and (nor-Leu11)-substance P strongly inhibited the binding. Good inhibition was also obtained with physalaemin and eledoisin, two peptides structurally related to substance P. When substance P C-terminal fragments were tested for their ability to compete with [125I]BHSP binding, a good relationship was found between competitive activity and peptide length. Regional distribution of [125I]BHSP binding sites was found using primary cultures obtained from different regions of embryonic mouse brain. Mesencephalic, hypothalamic, and striatal cultures had the highest [125I]BHSP binding capacities, whereas cortical, hippocampal, and cerebellar cells shared only little binding activity. Finally, when mesencephalic cells were grown under conditions impairing glial development, [125I]BHSP binding was not affected, demonstrating that binding sites are located on neuronal cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181386

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Interaction of tachykinins with their receptors studied with cyclic analogues of substance P and neurokinin B.

Authors:  O Ploux; S Lavielle; G Chassaing; S Julien; A Marquet; P d'Orléans-Juste; S Dion; D Regoli; J C Beaujouan; L Bergström
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Interactions between tachykinins and diverse, human nicotinic acetylcholine receptor subtypes.

Authors:  R J Lukas; C M Eisenhour
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

3.  International Substance P Symposium. Dublin, April 27-29, 1983. Abstracts.

Authors: 
Journal:  Ir J Med Sci       Date:  1983       Impact factor: 1.568

4.  Properties of a 125I-substance P derivative binding to synaptosomes from various brain structures and the spinal cord of the rat.

Authors:  Y Torrens; J C Beaujouan; A Viger; J Glowinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

5.  N-methyl-D-aspartate-activated channels of mouse central neurones in magnesium-free solutions.

Authors:  P Ascher; P Bregestovski; L Nowak
Journal:  J Physiol       Date:  1988-05       Impact factor: 5.182

6.  The postsynaptic targets of substance P-immunoreactive terminals in the rat neostriatum with particular reference to identified spiny striatonigral neurons.

Authors:  J P Bolam; P N Izzo
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

7.  Substance P receptors in primary cultures of cortical astrocytes from the mouse.

Authors:  Y Torrens; J C Beaujouan; M Saffroy; M C Daguet de Montety; L Bergström; J Glowinski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 8.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.